BioGaia Protectis® Family
60x Probiotic Lemon Flavored Chewable TabletsThe 1st probiotic in
chewable tablets worldwide (2000)
Unique probiotic with probiotic and prebiotic properties at the same time... by nature!
For gut health in children and adults
Antibiotic Gastrointestinal Disorders/Diarrhea/Constipation/Abdominal Pain/Vomiting INTENDEDFor children from 3 years and adults
- Contains the world's most studied probiotic strain in infants and children, one of the three most studied in adults
- Human strain, isolated in breast milk
- Absolutely safe for children and adults
- A natural colonist of our gastrointestinal tract from birth
- With a unique parallel natural prebiotic action due to its natural structure
- Clinically proven to colonize the entire gastrointestinal tract
- Clinically proven by clinical benefit and age group
- Clinically proven unique natural anti-pathogenic effect
- Safe for babies, children and adults, during pregnancy and breastfeeding and by diabetics
- It is protected by patents
- Does not contain sugar, lactose, gluten, milk protein
- Clinically proven in prevention and treatment of functional gastrointestinal disorders [(constipation / diarrhea (regulates bowel motility), reductions (increases rate of gastric emptying)]
- Scientifically proven to prevent and treat gastrointestinal disorders associated with taking antibiotics (diarrhea, abdominal pain, flatulence, etc.)
- Scientifically proven to improve the health and function of the digestive tract, home to 80% of our immunity
- Simple dosage regimen (1 tablet / day)
BioGaia Protectis® probiotic chewable tablets are a simple, natural, safe and easy way to restore and maintain healthy microbial balance in the gastrointestinal tract as well as improve digestive health and function
They contain L.reuteri Protectis® (L.reuteri DSM 17938), the patented probiotic bacterium of the Swedish company BioGaia. L.reuteri Protectis® was originally isolated in breast milk, it is the most studied probiotic worldwide in infants and children and one of the three most studied in adults. Its safety and effectiveness have been proven in 217 clinical studies and 180 scientific journal publications (last updated: January 2020).
L.reuteri Protectis® fully meets the requirements of the WHO. for probiotics. An in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over a five-day period showed that L. reuteri Protectis® was one of only three surviving strains. This fact was confirmed in vivo, when taken by healthy people led to significant colonization of the stomach, duodenum and ileum.
L. reuteri Protectis® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.
It is also the only probiotic that produces the antimicrobial substance reuterin against pathogenic microorganisms.
Contains the unique probiotic strain Limosilactobacillus reuteri Protectis®
(former name Lactobacillus reuteri Protectis®)
The unique Limosi natural substance – a Biofilm of Exopolysaccharides (EPSs) of high molecular weight – surrounding the probiotic strain L. Reuteri Protectis® also acts as a prebiotic for the symbiotic flora.
This biofilm:
a) Protects the probiotic strain it surrounds, from
- other microorganisms
- antibiotics
- toxic compounds
- osmotic stress
b) While for the organization
- It inhibits the adhesion of pathogens to the intestinal epithelium
- Supports the symbiotic microflora by acting as a prebiotic (food)
- Regulates immunity by activating T regulatory cells and increasing anti-inflammatory cytokines
BioGaia AB is a Swedish biotechnology company and global leader in probiotics, with a strong innovation profile, experience and expertise of over 30 years. To date, BioGaia AB holds more than 550 patents, commercial presence in more than 100 countries and physical presence in Europe, USA, China and Japan. BioGaia's vision is to improve people's health by offering probiotic products clinically documented and proven for their safety and efficacy by clinical benefit and age group. Until now (2/2020) BioGaia AB has completed more than 217 clinical studies, in infants, children and adults, and has proven the safety and effectiveness of its probiotic products in various disorders.
EAN: 7350012551988
